Summary by Moomoo AI
Novo Nordisk A/S, a leading global healthcare company, has announced the continuation of its share repurchase program, which began on February 6, 2024. As part of a 12-month plan to buy back shares worth up to DKK 20 billion, the company initiated a specific repurchase phase on May 6, 2024, with the intention to acquire B shares for up to DKK 2.2 billion between May 7, 2024, and August 5, 2024. Since the last update on June 3, 2024, Novo Nordisk has purchased an additional 154,000 B shares at an average price of DKK 950.28, amounting to a total transaction value of DKK 146,319,451. This brings the accumulated repurchases under the current program to 786,545 B shares, totaling DKK 724,234,837. As of June 7, 2024, the company has acquired 9,520,795 B shares at an average price of DKK 866.73 since the beginning of the repurchase plan, representing a total spend of DKK 8,251,969,609. Novo Nordisk now holds 10,886,359 B shares as treasury shares, which is 0.2% of the share capital. The company's shares are traded on Nasdaq Copenhagen and the New York Stock Exchange.